Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab

International Ophthalmology

Volumn 38, Issue 1, 2018, Pages 207-213

  Konidaris, Vasileios ^a   Al Hubeshy, Zahra ^a   Tsaousis, Konstantinos T ^a   Gorgoli, Konstantina ^a   Banerjee, Somnath ^a   Empeslidis, Theodoros ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Aflibercept; Anti VEGF; CRVO; Ranibizumab; Switching

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MACULAR EDEMA; MALE; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; TREATMENT DURATION; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG TOLERANCE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETINA MACULA LUTEA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85017441212     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-017-0512-8     Document Type: Article

References (28)

1. Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond) 25:981–988
2. Miller JW, Le Couter J, Strauss EC, Ferrara N (2013) Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120:106–114
3. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB (2014) Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 5:CD007325. doi:10.1002/14651858.CD007325.pub3
4. Ford JA, Clar C, Lois N, Barton S, Thomas S, Court R, Shyangdan D, Waugh N (2014) Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open 4:e004120. doi:10.1136/bmjopen-2013-004120
5. Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 1:8–15. doi:10.1159/000315155
6. Rezar-Dreindl S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Dunavölgyi R, Weigert G, Kroh ME, Schmidt-Erfurth U, Sacu S (2016) Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol. doi:10.1111/aos.13152
7. Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491
8. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE Investigators (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133
9. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. doi:10.1016/j.ophtha.2011.12.005
10. Campochiaro P, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219. doi:10.1016/j.ophtha.2013.08.038
11. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420
12. Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, GALILEO Study Group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038
13. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93:452–456
14. Zhang H, Liu Z, Sun P, Gu F (2011) Intravitreal bevacizumab for treatment of macular edema secondary to retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27:615–621
15. Aslankurt M, Aslan L, Aksoy A, Erden B, Cekic O (2013) The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 23:553–557
16. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15–22
17. Batioglu F, Demirel S, Ozmert E, Abdullayev A, Bilici S (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmol 15:40
18. Hanhart J, Chowers I (2015) Evaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edema. Case Rep Ophthalmol 6:44–50
19. Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL (2015) Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) 29:534–541
20. Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM, Wu D, Young LH, Kim IK, Vavvas DG, Esmaili DD, Husain D, Eliott D, Kim LA (2016) Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond) 30:79–84
21. Eadie JA, Ip MS, Kulkarni AD (2014) Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina 34:2439–2443
22. Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A (2015) The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd 232:552–555
23. Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J, Chiang A (2016) Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 51:342–347
24. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG (2013) Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 120:1057–1063
25. Ashraf M, Souka AA, Singh RP (2016) Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond) 30:505–514
26. Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J (2016) The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmol 94(5):e353–e355. doi:10.1111/aos.12832
27. Daien V, Navarre S, Fesler P, Vergely L, Villain M, Schneider C (2012) Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 22:1013–1018
28. Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S (2015) Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res 54:150–156